Wall Street analysts forecast that Portola Pharmaceuticals Inc (NASDAQ:PTLA) will announce ($1.05) earnings per share (EPS) for the current quarter, according to Zacks. Two analysts have made estimates for Portola Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($1.12) and the highest estimate coming in at ($0.96). Portola Pharmaceuticals posted earnings per share of ($1.61) during the same quarter last year, which would indicate a positive year-over-year growth rate of 34.8%. The company is expected to issue its next quarterly earnings report on Thursday, August 8th.
On average, analysts expect that Portola Pharmaceuticals will report full year earnings of ($4.13) per share for the current fiscal year, with EPS estimates ranging from ($4.20) to ($4.00). For the next fiscal year, analysts expect that the firm will post earnings of ($2.63) per share, with EPS estimates ranging from ($2.83) to ($2.35). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Portola Pharmaceuticals.
Portola Pharmaceuticals (NASDAQ:PTLA) last issued its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($1.02) EPS for the quarter, hitting analysts’ consensus estimates of ($1.02). Portola Pharmaceuticals had a negative return on equity of 238.48% and a negative net margin of 618.46%. The company had revenue of $22.17 million during the quarter, compared to analyst estimates of $20.60 million. During the same period in the previous year, the company earned ($1.28) earnings per share. The company’s quarterly revenue was up 233.9% compared to the same quarter last year.
A number of research analysts recently commented on the company. BidaskClub lowered Portola Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, May 21st. Cowen restated a “buy” rating on shares of Portola Pharmaceuticals in a research note on Wednesday, May 8th. Zacks Investment Research lowered Portola Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, May 2nd. ValuEngine lowered Portola Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. Finally, Oppenheimer set a $42.00 target price on Portola Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, April 12th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $42.29.
Shares of PTLA stock traded up $0.04 during trading hours on Friday, reaching $26.09. 14,740 shares of the company’s stock were exchanged, compared to its average volume of 1,050,826. Portola Pharmaceuticals has a fifty-two week low of $14.81 and a fifty-two week high of $44.25. The firm has a market cap of $1.77 billion, a PE ratio of -5.19 and a beta of 2.43. The company has a quick ratio of 4.77, a current ratio of 4.81 and a debt-to-equity ratio of 5.15.
In other Portola Pharmaceuticals news, Director Hollings Renton sold 5,000 shares of the company’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $34.45, for a total value of $172,250.00. Following the sale, the director now directly owns 14,000 shares in the company, valued at $482,300. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Mardi Dier sold 40,486 shares of the company’s stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $37.39, for a total value of $1,513,771.54. Following the completion of the sale, the chief financial officer now owns 66,733 shares in the company, valued at $2,495,146.87. The disclosure for this sale can be found here. Corporate insiders own 4.50% of the company’s stock.
A number of large investors have recently made changes to their positions in the business. BlackRock Inc. grew its holdings in shares of Portola Pharmaceuticals by 0.4% during the fourth quarter. BlackRock Inc. now owns 5,326,939 shares of the biopharmaceutical company’s stock worth $103,982,000 after purchasing an additional 19,532 shares during the last quarter. William Blair Investment Management LLC grew its holdings in shares of Portola Pharmaceuticals by 41.7% during the first quarter. William Blair Investment Management LLC now owns 4,154,870 shares of the biopharmaceutical company’s stock worth $144,174,000 after purchasing an additional 1,222,057 shares during the last quarter. Fiera Capital Corp bought a new stake in shares of Portola Pharmaceuticals during the first quarter worth $53,590,000. Brandywine Global Investment Management LLC grew its holdings in shares of Portola Pharmaceuticals by 11.8% during the fourth quarter. Brandywine Global Investment Management LLC now owns 834,967 shares of the biopharmaceutical company’s stock worth $16,299,000 after purchasing an additional 87,999 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in shares of Portola Pharmaceuticals by 3.4% during the first quarter. Northern Trust Corp now owns 830,822 shares of the biopharmaceutical company’s stock worth $28,831,000 after purchasing an additional 26,943 shares during the last quarter.
About Portola Pharmaceuticals
Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness.
Featured Article: How Investors Use a Balance Sheet
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.